Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Supervax
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Supervax is a prophylactic subunit vaccine for the prevention of hepatitis B virus (HBV) infection. It is composed of recombinant hepatitis B surface antigens (HBsAg) and the synthetic adjuvant RC-529, which is a monosaccharide analog of lipid A that functions as a Toll-like receptor 4 (TLR4) agonist. Unlike other lipid A-based adjuvants like MPL or GLA which have disaccharide backbones, RC-529 features a monosaccharide backbone. The vaccine was licensed in Argentina in 2003 and is administered as a two-dose regimen. Clinical data indicates that the RC-529-adjuvanted formulation provides significantly higher seroprotection rates and geometric mean anti-HBs titers compared to traditional aluminum-adjuvanted hepatitis B vaccines.
- Brand names
- Supervax
- Other names
- RC-529-adjuvanted hepatitis B vaccineRC529-adjuvanted hepatitis B vaccineRC 529-adjuvanted hepatitis B vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Supervax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Supervax.